| Similar Articles |
|---|
 |
The Motley Fool
August 27, 2007
Brian Orelli |
Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.   |
The Motley Fool
October 12, 2009
Brian Orelli |
Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
August 5, 2009
Brian Orelli |
Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data. |
The Motley Fool
March 22, 2005
Charly Travers |
Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials. |
The Motley Fool
April 8, 2008
Brian Orelli |
Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals... |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
The Motley Fool
May 7, 2008
Brian Orelli |
Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year. |
The Motley Fool
June 21, 2007
Billy Fisher |
A Bull-Run at Bristol The strength of its oncology pipeline sets Bristol-Myers apart from its peers. Regardless of whether the company is ultimately taken over, shareholders are definitely in a better position than they have been in recent years. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
November 8, 2007
Brian Orelli |
Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note. |
The Motley Fool
April 14, 2011
Brian Orelli |
One Step Closer to Revenue for Delcath But, between getting the Chemostat paid for in Europe and approved stateside, there's still plenty for Delcath to be worried about. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
The Motley Fool
April 12, 2011
Brian Orelli |
Delcath's Disappointing Delay The company said it will need an additional three months to resubmit the marketing application for its chemotherapy system. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM... |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing? |
BusinessWeek
January 13, 2011
Tara Lachapelle |
A Winning Stock Strategy: Sell on the Rumor Stocks that are the subject of takeover rumors jump, then fall, making short sales a winning strategy. Ignoring rumors works, too. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
The Motley Fool
April 29, 2004
Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
The Motley Fool
December 27, 2011
Rich Duprey |
Whoa! These Stocks Spread Some Holiday Cheer These stocks just took off, but are they about to make a return trip to Earth? |
The Motley Fool
October 13, 2011
Sean Williams |
How to Turn Onyx Into Gold A settlement with Bayer turns Onyx into an instant buyout candidate. |
